Skip to main content

Ben Johnson

More Than 10 Approved Gene Therapies and Over 465 Product Candidates are Being Evaluated for the Treatment of a Variety of Disease Indications

Currently, there are 11 gene therapies that have already received approval / conditional approval. In addition, there are more than 20 molecules in the advanced stages of clinical development (phase II/III and above) that are anticipated to soon enter the market. Further, we came across 213 gene therapy products that were either approved or are being developed in clinical stages and over 271 early stage (preclinical / discovery) candidates that are being investigated for various disorders. It is worth mentioning that more than two third of the gene therapies are in the early stages of clinical development (phase I/II and phase I), indicating that this domain has significant opportunity in the mid-long term.



Most of the pipeline drugs (36%) use AAV vectors as their preferred delivery vehicle. This can be attributed to the fact that these vectors offer various advantages, such as high titer, mild immunogenic response, the ability to infect a wide spectrum of cells and safety over other potential vectors. Other key vectors being used for the development of gene therapies include (in decreasing order of their popularity) non-viral vectors (20%), adenovirus vectors (18%) and lentivirus vectors (13%). In addition, 33% of the clinical candidates are being developed to target various oncological disorders. Unlike the clinical pipeline, within the preclinical / discovery pipeline, metabolic disorders (19%) have emerged as the most prominent therapeutic area.

In terms of modification, over 50% of the gene therapy candidates are modified through gene augmentation. This technique involves the addition of a functional copy of the gene in order to produce the missing proteins. Further, close to one-fourth of the therapies are immunotherapies, while about 17% of the candidates are oncolytic therapies. It is worth noting that immunotherapies are the therapies that stimulate the immune system to attack various disease-causing agents. On the other hand, oncolytic therapies use genetically modified viruses that selectively target and kill cancer cells. In case of gene therapies, these viruses act as vehicles to deliver the therapeutic agent to the cancer site.

In terms of route of administration, the intravenous route emerged as the most popular mode of injection for gene therapies; close to 30% therapy candidates are currently being developed to be delivered through this route of administration. Other prominent approaches being adopted by developers for the delivery of gene therapies include subretinal (11%), intramuscular (11%) and intratumoral (9%). It is important to mention that the subretinal route of administration is primarily adopted by gene therapies intended for the treatment of ophthalmic disorders.



Over the past few years, big pharmaceutical players, such as Amgen, Novartis and Pfizer, have either launched their gene therapy products or have advanced their clinical candidates towards later stages of development; however, the current market landscape is led by start-ups and mid-sized companies that have multiple gene therapy candidates in their pipeline.

Majority (57%) of the companies in this domain are small-sized firms (less than 50 employees); examples of such players include (in alphabetical order, established in 2017 and 2018) Actus Therapeutics, Apic Bio, Aruvant Sciences, Lacerta Therapeutics, Neurogene, Passage Bio, Pattern BioSciences, Prevail Therapeutics, Urovant Sciences, Verve Therapeutics and Wyvern Pharmaceuticals. In terms of geography, 63% of the companies developing gene therapies are headquartered in North America; of these, majority are based in the US. This is followed by companies (43) located in Europe. 

https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

Ben Johnson

The “Global Collaborative Robots (Cobots) Market, 2020-2030” report features an extensive study of the potential applications, current landscape and the likely adoption of cobots across various industrial applications, over the next decade.

4 min read

To order this detailed 245+ page report, please visit this link

 

Key Inclusions

§  An overview of the current market landscape of cobots, providing information on the market availability (available and under development), industrial task(s) performed (air blowing / spraying, CNC machine tending, gluing / dispensing / welding, loading / unloading, material handling, material removal / processing, packaging, palletizing, picking and placing, quality inspection, screw driving and small-part assembly), weight of cobots, payload capacity, degrees of freedom, maximum reach, position repeatability, number of arms, type of mounting, temperature of operational environment, end-user industry (aerospace, agriculture, automotive, food processing, electrical / electronic, life sciences / pharmaceutical, logistics, manufacturing, metal, and plastic and polymer), and cost of cobot. In addition, it presents details of the cobot manufacturers, highlighting year of establishment, company size, and location of headquarters.

§  An in-depth analysis of the contemporary market trends, presented using four schematic representations, including [A] an insightful heat map representation, highlighting the distribution of cobots on the basis of payload capacity and industrial task(s), [B] a tree map representation of the cobots, distributed on the basis of company size and end-users, and [C] a world map representation, highlighting the regional distribution of manufacturers.

§  Elaborate profiles of companies that are engaged in the development of cobots. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.

§  An insightful three-dimensional bubble chart representation, highlighting the competitiveness analysis of cobot manufacturers, taking into consideration the supplier strength (based on expertise of the manufacturer), product portfolio strength, portfolio diversity and number of industrial task(s) that can be performed.

§  A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as the experience of a cobot manufacturer, number of industrial task(s), number of products offered and product diversity.

§  A detailed competitiveness analysis of cobots based on various relevant parameters, such as supplier power (based on expertise of the manufacturer) and product specifications (payload capacity, maximum reach, number of arms, type of mounting, and number of industrial task(s) performed).

§  A discussion on key technological innovations (tools / technologies), such as advanced grippers, artificial intelligence, machine learning, vision technology and voice interface, in the cobots industry.

§  An insightful discussion on the effects of COVID-19 outbreak on the automation industry. It includes a brief discussion on the short-term and long-term impact of the disease outbreak on the market opportunity for developers.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

§  Payload Capacity

  • Below 6 Kg
  • Between 6 and 10 Kg
  • Above 10 Kg

 

§  Industrial Operation

  • Small Part Assembly
  • Case Packing
  • Material Handling
  • Palletizing / Depalletizing
  • Picking and Placing
  • Welding
  • Other Operations

 

§  End-User (Industry)

  • Automotive Industry
  • Food Processing Industry
  • Electrical / Electronic Industry
  • Plastic and Rubber Industry
  • Life Sciences / Pharmaceutical Industry
  • Metal Industry
  • Others

 

§  Key Geographical Regions 

  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

To request sample pages, please visit this link

 

Key Questions Answered

§  What are the key benefits and current limitations associated with the use of cobots?

§  Who are the leading players engaged in the manufacturing of cobots?

§  What are the most popular industrial applications of cobots?

§  What is the likely cost saving opportunity associated with the use of cobots?

§  How can end users prepare their workforce for interaction with cobots?

§  What impact is the recent COVID-19 pandemic likely to have on the global cobots market?

§  What opportunities are available for cobots manufacturers in emerging markets?

§  How is the current and future opportunity likely to be distributed across key market segments?

§  What are the anticipated future trends within the cobots market?

 

You may also be interested in the following titles:

1.      Deep Learning Market: Focus on Medical Image Processing, 2020-2030

2.      Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030

3.      AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

 

Ben Johnson

Over 230 cobots, having variable payload capacities and degrees of freedom, have already been deployed, or are being actively adopted across various industries, including the life sciences and pharmaceutical industry, claims Roots Analysis

2 min read

Collaborative robots or cobots allow companies to automate their processes, are easy to program and deploy, can increase productivity manifolds, and offer high returns on investment. It is worth noting that, according to the International Federation of Robotics (IFR), over time, the cost of cobots has decreased owing to growing demand for such machines across various industries, including automobiles, electronics / electrical goods, food and beverages, as well as life sciences / pharmaceuticals.

 

To order this 245+ page report, which features 80+ figures and 100+ tables, please visit this link

 

The USD 18 billion (by 2030) financial opportunity within the global cobots market has been analyzed across the following segments:

§  Payload Capacity

  • Below 6 Kg
  • Between 6 and 10 Kg
  • Above 10 Kg

 

§  Industrial Operation

  • Small Part Assembly
  • Case Packing
  • Material Handling
  • Palletizing / Depalletizing
  • Picking and Placing
  • Welding
  • Other Operations

 

§  End-User (Industry)

  • Automotive Industry
  • Food Processing Industry
  • Electrical / Electronic Industry
  • Plastic and Rubber Industry
  • Life Sciences / Pharmaceutical Industry
  • Metal Industry
  • Others

 

§  Key Geographical Regions 

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World

 

The Global Collaborative Robots (Cobots) Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

§  ABB

§  Comau

§  FANUC

§  Kinova

§  KUKA

§  Precise Automation

§  Robotics Systems Integration

§  Staubli

§  Universal Robots

§  Yaskawa Electric

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Current Market Landscape

5. Company Profiles

6. Company Competitiveness Analysis

7. Brand Positioning Analysis of Leading Players 

8. Product Competitiveness Analysis

9. Market Forecast

10. Impact of COVID-19 Pandemic on Cobots Market

11. Key Technological Innovations in Cobots Industry

12. Applications of Cobots: Use Cases

13. Executive Insights

14. Appendix I: Tabulated Data

 

15. Appendix II: List of Companies and Organizations

 

16. Appendix III: List of Distributors / Suppliers

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/collaborative-robots-market.html  

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected] 

 

Ben Johnson

The global collaborative robots (cobots) market is projected to grow at an annualized rate of 34.4%, till 2030

9 min read

Roots Analysis has done a detailed study on Global Collaborative Robots (Cobots) Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 245+ page report, which features 80+ figures and 100+ tables, please visit this link

 

Key Market Insights

§  Several players are currently engaged in the development and / or manufacturing of different types of cobots for a wide variety of operations, including both simple and precision tasks

§  Over 230 cobots, having variable payload capacities and degrees of freedom, have already been deployed, or are being actively adopted across various industries, including the life sciences and pharmaceutical industry

§  In order to achieve a competitive edge, several manufacturers are presently focusing on the integration of advanced technical features into their cobots portfolio for performing a variety of industrial task(s)

§  Companies involved in the development of industrial cobots are evenly distributed across the globe; it is worth noting that a number of start-ups claim to be working on cobots with advanced safety and hand guiding features

§  Stakeholders have already established strong brand positions; in fact, players are steadily expanding their respective portfolios, in order to maintain a competitive edge in this upcoming industry

§  Future growth of the market is likely to be driven by the need of automation in various industries; the opportunity is expected to be distributed across industrial operations, end-users, payload capacities and regions

 

For more information, please visit https://www.rootsanalysis.com/reports/collaborative-robots-market.html

 

Table of Contents

 

1.         PREFACE
1.1.      Scope of the Report
1.2.      Research Methodology
1.3.      Chapter Outlines

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.      Chapter Overview

3.2.      Collaborative Robots (Cobots)

3.2.1.    History of Cobots

3.2.2.    Cobots versus Traditional Industrial Robots

 

3.3.      Types of Cobots

3.4.      Advantages of Cobots

3.5.      Limitations of Cobots

3.6.      Type of End-Users

3.7.      Key Industrial Operation(s) Performed

3.8.      Regulatory Standards

3.9.      Key Considerations for Selection of a Cobot

3.10.     Estimation of Return on Investment (ROI) and Payback Period for Cobots

3.11.     Future Prospects

 

4.         CURRENT MARKET LANDSCAPE

4.1.      Chapter Overview

4.2.      Industrial Cobots: Overall Market Landscape

4.2.1.    Analysis by Market Availability

4.2.2.    Analysis by Type of Industrial Operation(s)

4.2.3.    Analysis by Weight of Cobot

4.2.4.    Analysis by Payload Capacity

4.2.5.    Analysis by Degrees of Freedom

4.2.6.    Analysis by Maximum Horizontal Reach

4.2.7.    Analysis by Positional Repeatability

4.2.8.    Analysis by Number of Arms

4.2.9.    Analysis by Type of Mounting

4.2.10.  Analysis by Temperature of Operational Environment

4.2.11.  Analysis by Type of End-User (Industry)

4.2.12.  Analysis by Cost of Cobot

 

4.3.      Industrial Cobots: Additional Information

 

4.4.      Industrial Cobots: Developer Landscape

4.4.1.    Analysis by Year of Establishment

4.4.2.    Analysis by Company Size

4.4.3.    Analysis by Location of Headquarters

4.4.4.    Analysis by Company Size and Location of Headquarters

 

4.5.      Leading Manufacturers: Analysis by Number of Cobots

4.6.       Heat Map Representation: Analysis by Payload Capacity and Industrial Operations

4.7.       Tree Map Representation: Analysis by Company Size and End-User

4.8.      World Map Representation: Analysis by Location of Headquarters

 

5.         COMPANY PROFILES

5.1.      Chapter Overview

5.2.      Leading Players based in North America

5.2.1.    Kinova

5.2.1.1. Company Overview

5.2.1.2. Product Portfolio

5.2.1.3. Recent Developments and Future Outlook

 

5.2.2.    Precise Automation

5.2.2.1. Company Overview

5.2.2.2. Product Portfolio

5.2.2.3. Recent Developments and Future Outlook

 

5.2.3.    Robotics Systems Integration

5.2.3.1. Company Overview

5.2.3.2. Product Portfolio

5.2.3.3. Recent Developments and Future Outlook

 

5.3.      Leading Players based in Europe

5.3.1.    ABB

5.3.1.1. Company Overview

5.3.1.2. Product Portfolio

5.3.1.3. Recent Developments and Future Outlook

 

5.3.2.    Comau

5.3.2.1. Company Overview

5.3.2.2. Product Portfolio

5.3.2.3. Recent Developments and Future Outlook

 

5.3.3.    FANUC

5.3.3.1. Company Overview

5.3.3.2. Product Portfolio

5.3.3.3. Recent Developments and Future Outlook

 

5.3.4.    KUKA

5.3.4.1. Company Overview

5.3.4.2. Product Portfolio

5.3.4.3. Recent Developments and Future Outlook

 

5.3.5.    Staubli

5.3.5.1. Company Overview

5.3.5.2. Product Portfolio

5.3.5.3. Recent Developments and Future Outlook

 

5.3.6.    Universal Robots

5.3.6.1. Company Overview

5.3.6.2. Product Portfolio

5.3.6.3. Recent Developments and Future Outlook

 

5.4.      Leading Players based in Asia-Pacific

5.4.1.    Yaskawa Electric

5.4.1.1. Company Overview

5.4.1.2. Product Portfolio

5.4.1.3. Recent Developments and Future Outlook

 

6.         COMPANY COMPETITIVENESS ANALYSIS

6.1.      Chapter Overview

6.2.      Assumptions / Key Parameters

6.3.      Methodology

6.4.       Company Competitiveness Analysis: Cobot Manufacturers in North America

6.5.       Company Competitiveness Analysis: Cobot Manufacturers in Europe

6.6.       Company Competitiveness Analysis: Cobot Manufacturers in Asia-Pacific and Rest of the World

 

7.         BRAND POSITIONING ANALYSIS OF LEADING PLAYERS

7.1.      Chapter Overview

7.2.      Key Parameters and Methodology

7.3.      Brand Positioning Matrix: ABB

7.4.      Brand Positioning Matrix: FANUC

7.5.      Brand Positioning Matrix: KUKA

7.6.      Brand Positioning Matrix: Staubli

7.7.      Brand Positioning Matrix: Universal Robots

7.8.      Brand Positioning Matrix: Yaskawa Electric

 

8.         PRODUCT COMPETITIVENESS ANALYSIS

8.1.      Chapter Overview

8.2.      Assumptions / Key Parameters

8.3.      Methodology

8.4.       Product Competitiveness Analysis: Cobots with Less than Six Degrees of Freedom

8.5.       Product Competitiveness Analysis: Cobots with Six Degrees of Freedom

8.6.       Product Competitiveness Analysis: Cobots with More than Six Degrees of Freedom

 

9.         MARKET FORECAST

9.1.       Chapter Overview

9.2.      Forecast Methodology and Key Assumptions

9.3.       Overall, Global Cobots Market, 2020-2030

 

9.3.1.    Global Cobots Market: Distribution by Payload Capacity

9.3.1.1. Market for Cobots with Payload Capacity below 6 Kg, 2020-2030

9.3.1.2. Market for Cobots with Payload Capacity between 6 and 10 Kg, 2020-2030

9.3.1.3. Market for Cobots with Payload Capacity above 10 Kg, 2020-2030

 

9.3.2.    Global Cobots Market: Distribution by Industrial Operation(s)

9.3.2.1. Cobots Market for Small Part Assembly Operations, 2020-2030

9.3.2.2. Cobots Market for Case Packing Operations, 2020-2030

9.3.2.3. Cobots Market for Material Handling Operations, 2020-2030

9.3.2.4. Cobots Market for Palletizing / Depalletizing Operations, 2020-2030

9.3.2.5. Cobots Market for Picking and Placing Operations, 2020-2030

9.3.2.6. Cobots Market for Welding Operations, 2020-2030

9.3.2.7. Cobots Market for Other Operations, 2020-2030

 

9.4.3.    Global Cobots Market: Distribution by End-User (Industry)

9.4.3.1. Cobots Market for Automotive Industry, 2020-2030

9.4.3.2. Cobots Market for Food Processing Industry, 2020-2030

9.4.3.3. Cobots Market for Electrical / Electronic Industry, 2020-2030

9.4.3.4. Cobots Market for Plastic and Rubber Industry, 2020-2030

9.4.3.5. Cobots Market for Life Sciences / Pharmaceutical Industry, 2020-2030

9.4.3.6. Cobots Market for Metal Industry, 2020-2030

9.4.3.7. Cobots Market for Other Industries, 2020-2030

 

9.4.4.    Global Cobots Market: Geographical Distribution

9.4.4.1. Cobots Market in North America, 2020-2030

9.4.4.1.1. Cobots Market in the US, 2020-2030

9.4.4.1.2. Cobots Market in Canada, 2020-2030

 

9.4.4.2. Cobots Market in Europe, 2020-2030

9.4.4.2.1. Cobots Market in Germany, 2020-2030

9.4.4.2.2. Cobots Market in France, 2020-2030

9.4.4.2.3. Cobots Market in Italy, 2020-2030

9.4.4.2.4. Cobots Market in Spain, 2020-2030

9.4.4.2.5. Cobots Market in the UK, 2020-2030

9.4.4.2.6. Cobots Market in Rest of Europe, 2020-2030

 

9.4.4.3. Cobots Market in Asia-Pacific and Rest of the World, 2020-2030

9.4.4.3.1. Cobots Market in China, 2020-2030

9.4.4.3.2. Cobots Market in India, 2020-2030

9.4.4.3.3. Cobots Market in Japan, 2020-2030

9.4.4.3.4. Cobots Market in South Korea, 2020-2030

 

10.       IMPACT OF COVID-19 PANDEMIC ON COBOTS MARKET

10.1.     Chapter Overview

10.2.     Impact of COVID-19 Outbreak on Automation Industry

10.3.     Impact on Future Market Opportunity for Global Cobots Market

 

11.       KEY TECHNOLOGICAL INNOVATIONS IN COBOTS INDUSTRY

11.1.     Chapter Overview

11.2.     Advanced Grippers

11.2.1.  New Sensor Technologies for Higher Gripping Forces

11.3.     Artificial Intelligence (AI) and Machine Learning

11.4.     Vision Technology

11.5.     Voice Interfaces

11.6.     End-of-Arm Tooling (EoAT)

11.7.     Concluding Remarks

 

12.       APPLICATIONS OF COBOTS: USE CASES

12.1.     Chapter Overview

12.2.     Example Applications of Cobots across Various Industries

12.2.1.  Agriculture Industry

12.2.2.  Automotive Industry

12.2.3.  Construction Industry

12.2.4.  Electric / Electronic Industry

12.2.5.  Food Processing Industry

12.2.6.  Life Science / Pharmaceutical Industry

12.2.7.  Logistics and Warehousing Industry

12.2.8.  Metal Industry

12.2.9.  Oil and Gas Industry

12.2.10. Textile Industry

 

13.       EXECUTIVE INSIGHTS

13.1.     Chapter Overview

 

13.2.     ROBOMOV

13.2.1. Company Snapshot

13.2.2. Interview Transcript: Mineko Ogata, Owner

 

13.3       Giga Automata

13.3.1.  Company Snapshot

13.3.2.  Interview Transcript: Georgi Arabadzhiev, Co-founder

 

13.4.     ST Robotics

13.4.1.  Company Snapshot

13.4.2.  Interview Transcript: David Sans, Chief Executive Officer

 

13.5.     Fetch Robotics

13.5.1.  Company Snapshot

13.5.2.  Interview Transcript: Barry Philips, Chief Marketing Officer

 

13.6.     Precise Automation

13.6.1.  Company Snapshot

13.6.2.  Interview Transcript: Brian Carlisle, President

 

13.7.     CSM Technologies

13.7.1.  Company Snapshot

13.7.2.  Interview Transcript: Nilabdhi Samantray (Associate Vice President, Head of Data Science and Artificial Intelligence, Sector Leader (Mines and Minerals)

 

13.8.     Tekpak Automation

13.8.1.  Company Snapshot

13.8.2.  Interview Transcript: John Kehoe, Managing Director

 

13.9.     SMC Austria

13.9.1.  Company Snapshot

13.9.2.  Interview Transcript: Andreas Czezatke, Global Project Leader

 

13.10.   F&P Robotics

13.10.1. Company Snapshot

13.10.2. Interview Transcript: Nelija Miseikiene, Sales and Marketing Specialist

 

13.11.   Productive Robotics

13.11.1. Company Snapshot

13.11.2. Interview Transcript: Michael Murray, Sales Specialist

 

13.12.   Universal Robots

13.12.1. Company Snapshot

13.12.2. Interview Transcript: Aadya Avinash, Assistant Marketing Manager

 

14.  APPENDIX I: TABULATED DATA

 

15.  APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

 

16.  APPENDIX III: LIST OF DISTRIBUTORS / SUPPLIERS



 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

 

Ben Johnson

The global collaborative robots (cobots) market is projected to be worth USD 18 billion by 2030, growing at a CAGR of 34.4%, claims Roots Analysis

4 min read

Given their flexibility and price to functionality ratio, cobots represent an ideal entry-level, automation model for both small and established companies, which do not intend to make very heavy large investments in automation

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Collaborative Robots (Cobots) Market, 2020-2030.

 

The report features an extensive study of the potential applications, current landscape and the likely adoption of cobots across various industrial applications, over the next decade. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:

§  An overview of the current market landscape of cobots and details of the cobot manufacturers.

§  An in-depth analysis of the contemporary market trends presented using four schematic representations.

§  Elaborate profiles of companies that are engaged in the development of cobots.

§  An insightful three-dimensional bubble chart representation, highlighting the competitiveness analysis of cobot manufacturers.

§  A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary products.

§  A detailed competitiveness analysis of cobots based on various relevant parameters.

§  A discussion on key technological innovations (tools / technologies), such as advanced grippers, artificial intelligence, machine learning, vision technology and voice interface, in the cobots industry.

§  An insightful discussion on the effects of COVID-19 outbreak on the automation industry.

 

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Payload Capacity

  • Below 6 Kg
  • Between 6 and 10 Kg
  • Above 10 Kg

 

§  Industrial Operation

  • Small Part Assembly
  • Case Packing
  • Material Handling
  • Palletizing / Depalletizing
  • Picking and Placing
  • Welding
  • Other Operations

 

§  End-User (Industry)

  • Automotive Industry
  • Food Processing Industry
  • Electrical / Electronic Industry
  • Plastic and Rubber Industry
  • Life Sciences / Pharmaceutical Industry
  • Metal Industry
  • Others

 

§  Key Geographical Regions 

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World  

 

Transcripts of interviews held with the following senior level representatives of stakeholder companies

§  Mineko Ogata (Owner, ROBOMOV)

§  David Sands (Chief Executive Officer, ST Robotics)

§  Barry Philips (Chief Marketing Officer, Fetch Robotics)

§  Brian Carlisle (President, Precise Automation)

§  Nilabdhi Samantray (Associate Vice President, Head of Data Science and Artificial Intelligence, Sector Leader (Mines and Minerals), CSM Technologies)

§  John Kehoe (Managing Director, Tekpak Automation)

§  Andreas Czezatke (Global Project Leader, SMC Austria)

§  Nelija Miseikiene (Sales and Marketing Specialist, F&P Robotics)

§  Michael Murray (Sales Specialist, Productive Robotics)

§  Aadya Avinash (Assistant Marketing Manager, Universal Robots)

 

Key companies covered in the report

§  ABB

§  Comau

§  FANUC

§  Kinova

§  KUKA

§  Precise Automation

§  Robotics Systems Integration

§  Staubli

§  Universal Robots

§  Yaskawa Electric

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/collaborative-robots-market.html   

 

Other Recent Offerings

1.      Deep Learning Market: Focus on Medical Image Processing, 2020-2030

2.      Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030

3.      AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

 

Ben Johnson

The global autoinjectors market is projected to grow at an annualized rate of ~10% and be worth around USD 2.5 Billion, till 2030

46 min read

Roots Analysis has done a detailed study on Global Autoinjectors Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this link

 

Key Market Insights

§  Currently, several companies claim to be engaged in the development / manufacturing of various types of autoinjectors, most of which are disposable systems that use prefilled syringes as primary drug containers

§  About 90 autoinjector-based combination products have been approved for the treatment of a variety of clinical conditions; the subcutaneous route being the preferred mode of drug delivery via such devices

§  In order to gain a competitive edge in the market, many autoinjector manufacturers are focusing on the integration of advanced features into their respective products and affiliated offerings

§  Over time, more than 4,600 patents have been filed / granted related to autoinjectors and affiliated products; most of the new intellectual property is related to additional features, such as safety locks and device connectivity

§  Eminent scientists from renowned organizations and academic institutions across the world have made valuable contributions to this field, in terms of leading clinical research efforts and developing novel technologies

§  Several autoinjector developers have established strong brand positions in different geographies; the focus, in the near term, is likely to be on further enhancing device features for better disease management and improved patient compliance

§  An evaluation of 200+ marketed and pipeline products revealed that a variety of drugs / product candidates are likely to be considered for administration via autoinjectors in the near future

§  Case Study: Owing to the complexities associated with the manufacturing and assembly of autoinjector drug delivery systems, industry players are known to frequently engage the services of contract service providers

§  Currently, disposable autoinjector products for small molecule drugs dominate the market; however, in the foreseen future, the demand for reusable devices is anticipated to witness significant growth

§  Given the recent approvals and presence of multiple drug candidates in later stages of development, the market opportunity is likely to be distributed across different therapeutic areas, routes of administration and geographies

 

For more information, please visit  https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html

 

Table of Contents

 

1.              PREFACE

1.1.           Scope of the Report

1.2.           Research Methodology

1.3.           Chapter Outlines

 

2.              EXECUTIVE SUMMARY

                

3.              INTRODUCTION

3.1.           Chapter Overview

3.2.           Types of Drug Delivery Systems

3.3.           Drawbacks of Conventional Parenteral Delivery Systems

3.4.           Needlestick Injuries

3.4.1.        Incidence and Cost Burden

3.4.2.        Government Legislation for the Prevention of Needlestick Injuries          

                

3.5.           Emerging Trend of Self-Administration

3.5.1.        Rising Burden of Chronic Diseases

3.5.2.        Healthcare Cost Savings

3.5.3.        Need for Immediate Treatment in Emergency Situations

3.5.4.        Growth of Injectable Biologics Market

3.5.5.        Addressing Key User Safety Requirements

                

3.6.           Types of Self- Administration Devices

3.6.1.        Prefilled Syringes

3.6.2.        Pen-Injectors

3.6.3.        Needle-Free Injectors

3.6.4.        Autoinjectors

3.6.5.        Large Volume Wearable Injectors

                

3.7.           Overview of Autoinjectors

3.7.1.        Components of Autoinjectors

3.7.2.        Classification of Autoinjectors

3.7.2.1.     On the Basis of Mechanism of Action

3.7.2.2.     On the Basis of Usability

3.7.2.3.     On the Basis of Type of Dose

3.7.3.        Manufacturing / Packaging of Autoinjectors

3.7.4.        Benefits of Autoinjectors

                

3.8.           Regulatory Considerations

3.8.1.        Medical Devices

3.8.2.        Drug Device Combination Products

 

3.9.           Future Perspectives

                

4.              PRIMARY DRUG CONTAINERS

4.1.           Chapter Overview

4.2.           Types of Packaging

4.3.           Introduction to Primary Drug Containers

4.3.1.        Role of Primary Drug Containers

4.3.2.        Types of Primary Drug Containers

4.3.2.1.     Cartridges

4.3.2.1.1.   Components of Cartridges

4.3.2.1.2.   Types of Cartridges

4.3.2.1.2.1. Single Chamber Cartridge

4.3.2.1.2.2. Dual Chamber Cartridge

4.3.2.1.3.   Cartridges Available in the Market

                

4.3.2.2.     Syringes

4.3.2.2.1.   Components

4.3.2.2.2.   Types of Syringes

4.3.2.2.2.1. Based on Number of Chambers

4.3.2.2.2.2. Based on Type of Needle

4.3.2.2.3.   Prefilled Syringe Systems Available in the Market

4.3.2.2.3.1. Glass Prefilled Syringes

4.3.2.2.3.2. Plastic Prefilled Syringes

                

4.3.2.3.     Vials

4.3.2.3.1.   Components

4.3.2.3.2.   Vials Available in the Market

 

4.4.           Comparison of Fabrication Materials

                

5.              AUTOINJECTORS: CURRENT MARKET LANDSCAPE

5.1.           Chapter Overview

5.2.           Autoinjectors: List of Devices

5.2.1.        Analysis by Usability

5.2.2.        Analysis by Type of Primary Container

 

5.3.           Autoinjectors: List of Additional Parameters of Devices

5.3.1.        Analysis by Volume of Container

5.3.2.        Analysis by Type of Dose

5.3.3.        Analysis by Route of Administration

5.3.4.        Analysis by Actuation Mechanism

5.3.5.        Analysis by Type of Feedback Mechanism

                

5.4.           Autoinjectors: List of Developers

5.4.1.        Analysis by Year of Establishment

5.4.2.        Analysis by Company Size

5.4.3.        Analysis by Geographical Location of Headquarters

                

6.              PRODUCT COMPETITIVENESS ANALYSIS

6.1.           Chapter Overview

6.2.           Methodology

6.3.           Assumptions and Key Parameters

6.4.           Product Competitiveness Analysis

6.4.1.        Disposable Autoinjectors

6.4.2.        Reusable Autoinjectors

                

7.              BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS

7.1            Chapter Overview

7.2.           Scope and Methodology

7.3.           Brand Positioning Matrix: Antares Pharma

7.4.           Brand Positioning Matrix: BD

7.5.           Brand Positioning Matrix: DALI Medical Devices

7.6.           Brand Positioning Matrix: Elcam Drug Delivery Devices

7.7.           Brand Positioning Matrix: Oval Medical Technologies

7.8            Brand Positioning Matrix: Owen Mumford

7.9.           Brand Positioning Matrix: SHL Medical

7.10          Brand Positioning Matrix: Union Medico

7.11.         Brand Positioning Matrix: Ypsomed

                

8.              PATENT ANALYSIS

8.1.           Chapter Overview

8.2.           Scope and Methodology

8.3.           Autoinjectors: Patent Analysis

8.3.1.        Analysis by Application Year

8.3.2.        Analysis by Issuing Authority

8.3.3.        Analysis by CPC Symbols

 

8.4.           Emerging Areas

8.5.           Leading Players Based on Number of Patents

8.6.           Autoinjectors: Patent Benchmarking Analysis

8.6.1.        Analysis by Patent Characteristics

8.6.2.        Analysis by Geography

 

8.7.           Autoinjectors: Patent Valuation Analysis

                

9.              THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS

9.1.           Chapter Overview

9.2.           Autoinjector Combination Products: List of Approved Drugs

9.2.1.        Analysis by Initial Year of Approval

9.2.2.        Analysis by Usability

9.2.3.        Analysis by Route of Administration

9.2.4.        Analysis by Primary Drug Container

 

9.3.           Approved Autoinjector Combination Products: List of Additional Parameters

9.3.1.        Analysis by Type of Molecule

9.3.2.        Analysis by Dose Strength

9.3.3.        Analysis by Therapeutic Indication

9.3.4.        Analysis by Other Packaging Formats of Marketed Drugs

 

9.4.           Autoinjector Combination Products: List of Pipeline Drugs

9.4.1.        Analysis by Phase of Development

 

9.5.           Pipeline Autoinjector Combination Products: List of Additional Parameters

9.5.1.        Analysis by Route of Administration

9.5.2.        Analysis by Type of Molecule

9.5.3.        Analysis by Therapeutic Indication

9.5.4.        Grid Analysis: Distribution by Therapeutic Indication, Phase of Development and Route of Administration

                

9.6.           Autoinjector Combination Products: List of Developers

9.6.1.        Analysis by Year of Establishment

9.6.2.        Analysis by Company Size

9.6.3.        Analysis by Location of Headquarters

                

10.            CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS

10.1.         Chapter Overview

10.2.         Marketed / Pipeline Drugs Being Evaluated with Autoinjectors

10.3.         Case Study I: Anaphylaxis

10.3.1.      Overview and Epidemiology

10.3.2.      Adrenaline: Mechanism of Action

10.3.3.      History of Development

 

10.3.4.      Marketed Adrenaline / Epinephrine Autoinjectors

10.3.4.1.    Adrenaclick

10.3.4.2.    Allerject / Auvi-Q (Formerly called e-cue)

10.3.4.3.    Anapen

10.3.4.4.    Emerade

10.3.4.5.    EpiPen / EpiPen Jr

10.3.4.6.    Jext

10.3.4.7.    EpiPen / EpiPen Jr

 

10.3.5.      Adrenaline / Epinephrine Autoinjectors Under Development

10.3.5.1.    EpiQ

10.3.5.2.    ANDIPen

10.3.5.3.    MiniEpi

10.3.5.4.    Zeneo Adrenaline

 

10.3.6.      Other Dosage Forms

10.3.7.      Historical Sales of Approved Drugs / Autoinjectors

                

10.4.         Case Study II: Multiple Sclerosis

10.4.1.      Overview and Epidemiology

10.4.2.      Interferon β-1a

10.4.3.      Interferon β-1b

10.4.4.      Interferons: Mechanism of Action

10.4.5.      History of Development

 

10.4.6.      Interferon β-1a Autoinjectors

10.4.6.1.    Avonex Pen

10.4.6.2.    PLEGRIDY Pen

10.4.6.3.    Rebif Rebidose

10.4.6.4.    RebiSmart

10.4.6.5.    Rebiject II

10.4.6.6.    ReciGen Physioject

 

10.4.7.      Interferon β-1b Autoinjectors

10.4.7.1.    BETACONNECT

10.4.7.2.    BETAJECT Comfort / Betacomfort

10.4.7.3.    Betaject Lite

10.4.7.4.    ExtaviJect 30G / ExtaviPro 30G

 

10.4.8.      Other Marketed Autoinjectors

10.4.8.1.    Cinnomer40 Physioject

10.4.8.2.    CSYNC Autoinjector

10.4.8.3.    WhisperJECT

10.4.8.4.    Remurel Autoxon

 

10.4.9.      Other Dosage Forms

10.4.10.     Historical Sales of Approved Drugs / Autoinjectors

10.4.10.1.  Interferon β-1a

10.4.10.2.  Interferon β-1b

 

10.5.         Case Study III: Migraine

10.5.1.      Overview and Epidemiology

10.5.2.      Sumatriptan Succinate: Mechanism of Action

10.5.3.      History of Development

10.5.4.      Marketed Autoinjectors

10.5.4.1.    ALSUMA

10.5.4.2.    IMITREX STATdose Pen

10.5.4.3.    Zembrace SymTouch

10.5.4.4.    Aimovig SureClick Autoinjector

10.5.4.5.    Emgality Prefilled Pen

 

10.5.5.      Other Dosage Forms

10.5.6.      Historical Sales of Approved Drugs / Autoinjectors

                

10.6.         Case Study IV: Rheumatoid Arthritis

10.6.1.      Overview and Epidemiology

10.6.2.      History of Development

 

10.6.3.      Marketed Autoinjectors for Rheumatoid Arthritis

10.6.3.1.    Actemra

10.6.3.2.    CIMZIA AutoClicks Prefilled Pen

10.6.3.3.    Enbrel SureClick

10.6.3.4.    Hulio Prefilled Pen

10.6.3.5.    HUMIRA Pen

10.6.3.6.    ORENCIA ClickJect

10.6.3.7.    OTREXUP

10.6.3.8.    Rasuvo Autoinjector

10.6.3.9.    SIMPONI SmartJect Autoinjector

10.6.3.10.  KEVZARA Prefilled Pen

10.6.3.11.  IMRALDI Prefilled Pen

 

10.6.4.      Historical Sales of Approved Drugs / Autoinjectors

                

11.            LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS

11.1.         Chapter Overview

11.2.         Methodology and Key Parameters

11.3.         Marketed Drug Candidates for Delivery via Autoinjectors

11.3.1.      Most Likely Drug Candidates

11.3.2.      Likely Drug Candidates

11.3.3.      Less Likely Drug Candidates

11.3.4.      Unlikely Drug Candidates

 

11.4.         Clinical Drug Candidates for Delivery via Autoinjectors

11.4.1.      Most Likely Drug Candidates

11.4.2.      Likely Drug Candidates

11.4.3.      Less Likely Drug Candidates

11.4.4.      Unlikely Drug Candidates

                

12.            KEY PLAYERS

12.1.         Chapter Overview

12.2.         Antares Pharma

12.2.1.      Company Overview

12.2.2.      Financial Information

12.2.3.      Product Portfolio

12.2.3.1.    Autoinjectors: Product Details

12.2.3.1.1. Vibex

12.2.3.1.2. QuickShot

12.2.3.1.3. BigShot

 

12.2.4.      Collaborators

12.2.4.1.    Teva Pharmaceutical

12.2.4.2.    Ferring Pharmaceuticals

12.2.4.3.    AMAG Pharmaceuticals

12.2.4.4.    JCR Pharmaceuticals

12.2.4.5.    Pfizer

12.2.4.6.    Idorsia Pharmaceuticals

 

12.2.5.      Recent Developments and Future Outlook

                

12.3          Consort Medical (Previously Bespak)

12.3.1.      Company Overview

12.3.2.      Financial Information

12.3.3.      Technology Overview

12.3.4.      Product Portfolio

12.3.4.1.    Autoinjectors: Product Details

12.3.4.1.1. Syrina

12.3.4.1.2. OTS Autoinjector

12.3.4.1.3. Viscala Autoinjector

 

12.3.5.      Collaborators

12.3.5.1.    Aesica Pharmaceuticals

12.3.5.2.    Undisclosed Global Biopharmaceutical Company

12.3.5.3.    Regeneron Pharmaceuticals

 

12.3.6.      Recent Developments and Future Outlook

                

12.4.         DALI Medical Devices

12.4.1.      Company Overview

12.4.2.      Product Portfolio

12.4.2.1.    Autoinjectors: Product Details

12.4.2.1.1. SAN-L

12.4.2.1.2. SAN-P

12.4.2.1.3. SAN-DV

12.4.2.1.4. SAN-DV Pro

12.2.2.1.5. SAN-Light

 

12.4.3.      Collaborators

12.4.3.1.    Elcam Drug Delivery Devices

 

12.4.4.      Recent Developments and Future Outlook

                

12.5.         Elcam Medical (E3D Elcam Drug Delivery Devices)

12.5.1.      Company Overview

12.5.2.      Product Portfolio

12.5.2.1.    Autoinjectors: Product Details

12.5.2.1.1. Flexi-Q Disposable Autoinjectors

12.5.2.1.1.1.     Flexi-Q PFS

12.5.2.1.1.2.     Flexi-Q HV

12.5.2.1.1.3.     Flexi -Q DV

 

12.5.2.1.2. Flexi-Q Reusable Autoinjectors

12.5.2.1.2.1.     Flexi-Q mMU

12.5.2.1.2.2.     Flexi-Q eMU-C / P

12.5.2.1.2.3.     Flexi-Q EAI

 

12.5.3.      Comparison of Elcam Medical Autoinjectors

12.5.4.      Collaborators

12.5.4.1.    DALI Medical Devices

 

12.5.5.      Recent Developments and Future Outlook

                

12.6.         Jiangsu Delfu Medical Devices

12.6.1.      Company Overview

12.6.2.      Financial Information

12.6.3.      Product Portfolio

12.6.3.1.    Autoinjectors: Overview and Specifications

12.6.3.1.1. Components of Delfu Autoinjectors

12.6.3.1.2. Applications of Delfu Autoinjectors

12.6.3.1.3. Features of Delfu Autoinjectors

12.6.3.1.4. Advantages of Delfu Autoinjectors

12.6.3.1.5. Specifications of Delfu Autoinjectors

 

12.6.3.2.    Autoinjectors: Product Details

12.6.3.2.1. YZ-II 3mL Cartridge Digital Dose Setting GF Autoinjector

12.6.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector

12.6.3.2.3. DZ-IA Auto Injector Pen

12.6.3.2.4. Intravitreal Anti-VEGF Injections Electric Insulin Pens

12.6.3.2.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen

12.6.3.2.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors

12.6.3.2.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen

12.6.3.2.8. YZ-II 3mL* 1u Auto Injector Pen

12.6.3.2.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen

12.6.3.2.10. YZ-III Automatic Reusable Insulin Injection Pen

 

12.6.4.      Recent Developments and Future Outlook

                

12.7.         Oval Medical Technologies

12.7.1.      Company Overview

12.7.2.      Product Portfolio

12.7.2.1.    Autoinjectors: Product Details

12.7.2.1.1  ArQ

12.7.2.1.2  ArQ - Bios

12.7.2.1.3  ArQ - Tempo

12.7.2.1.4  ArQ - Vita

 

12.7.3.      Collaborators

12.7.3.1.    SOLIZE

 

12.7.4.      Recent Developments and Future Outlook

                

12.8.         Owen Mumford

12.8.1.      Company Overview

12.8.2.      Product Portfolio

12.8.2.1.    Autoinjectors: Product Details

12.8.2.1.1. Autoject Micro

12.8.2.1.2. Autoject 2

12.8.2.1.3. Autoject Mini

12.8.2.1.4. Autoject Visco

12.8.2.1.5. UniSafe Auto-injector

12.8.2.1.6. UniSafe Connected Auto-injector

 

12.8.3.      Collaborators

12.8.3.1.    Nipro

12.8.3.2.    Sanofi Aventis

 

12.8.4.      Recent Developments and Future Outlook

                

12.9.         SHL Group

12.9.1.      Company Overview

12.9.2.      Product Portfolio

12.9.2.1.    Two-Step Disposable Autoinjectors: Product Details

12.9.2.1.1  Amber (Pushclick Technology)

12.9.2.1.2. Molly

12.9.2.1.3. Molly RNS

12.9.2.1.4. Molly 2.25

12.9.2.1.5. Rotaject

12.9.2.1.6. Bertha

12.9.2.1.7. DAI 2

12.9.2.1.8. Maggie

12.9.2.1.9. Comparison of SHL Two-Step Autoinjectors

 

12.9.2.2.    Three-Step Disposable Autoinjectors: Product Details

12.9.2.2.1. DAI

12.9.2.2.2. SDI-MIX+NIT (Needle Isolation Technology and Twist and Mix Mechanism)

12.9.2.2.3. VSDI+NIT

12.9.2.2.4. Comparison of SHL Three-Step Autoinjectors

12.9.2.3.    PPI Injector (Rotaject Pressure Release Technology)

 

12.9.4.      Collaborators

12.9.4.1.    Schreiner MediPharm

12.9.4.2.    QuiO

 

12.9.5.      Recent Developments and Future Outlook

                

12.10.       Union Medico

12.10.1.     Company Overview

12.10.2.     Technology Overview

12.10.3.     Product Portfolio

12.10.3.1.  Autoinjectors: Product Details

12.10.3.1.1 45˚ Autoinjector

12.10.3.1.2 45˚/ S Autoinjector

12.10.3.1.3 45˚/ M Autoinjector

12.10.3.1.4 45˚/ R Autoinjector

12.10.3.1.5 Comparison of 45˚ Autoinjectors

12.10.3.1.6 90˚Autoinjector

12.10.3.1.7 90˚/ S Autoinjector

12.10.3.1.8 90˚/ M Autoinjector

12.10.3.1.9 90˚/ XL Autoinjector

12.10.3.1.10      SuperGrip Autoinjector

12.10.3.1.11      Exclusive Autoinjector

12.10.3.1.12      Comparison of 90˚ Autoinjectors

 

12.10.4.     Recent Developments and Future Outlook

                

12.11.       Ypsomed

12.11.1.     Company Overview

12.11.2.     Financial Information

12.11.3.     Product Portfolio

12.11.3.1.  Autoinjectors: Product details

12.11.3.1.1. YpsoMate ,YpsoMate 2.25 and YpsoMate 2.25Pro

12.11.3.1.2. VarioJect

12.11.3.1.3. LyoTwist Trio, LyoTwist Trio S, LyoTwist Vario and LyoTwist Vario S

12.11.3.1.4. Comparison of Autoinjectors

 

12.11.4.     Collaborators

12.11.4.1.  Royal Philips

 

12.11.5.     Recent Developments and Future Outlook

                

13.            EMERGING PLAYERS

13.1.         Chapter Overview

13.2.         AktiVax

13.3.         Amneal Pharmaceuticals

13.4.         kaléo

13.5.         Nemera

13.6.         Nuance Designs

13.7.         Windgap Medical

13.8.         Xeris Pharmaceuticals

13.9.         Zion Clinical Pharmacy

                

14.            KOL ANALYSIS

14.1.         Chapter Overview

14.2.         Methodology

14.3.         KOL Analysis: Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials

14.3.1.      Geographical Distribution of KOLs

14.3.2.      KOL Benchmarking

 

14.3.         KOL Analysis: Patent Assignees

14.3.1.      Geographical Distribution of KOLs

                

15.            SWOT ANALYSIS

15.1.         Chapter Overview

15.2.         Strengths

15.3.         Weaknesses

15.4.         Opportunities

15.5.         Threats

15.6.         Concluding Remarks

                

16.            CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS

16.1.         Chapter Overview

16.2.         Challenges Associated with Medical Device Manufacturing

16.3.         Role of CMOs in Medical Device Manufacturing

16.4.         Services Offered by Medical Device CMOs

16.5.         Advantages Offered by Medical Device CMOs

16.6.         Risks Associated with Outsourcing to CMOs

16.7.         Drug Delivery Service Providers

16.7.1.      Analysis by Year of Establishment

16.7.2.      Analysis by Company Size

16.7.3.      Analysis by Geography

16.7.4.      Analysis by Types of Services

16.8.         Concluding Remarks

 

17.            MARKET SIZING AND OPPORTUNITY ANALYSIS

17.1.         Chapter Overview

17.2.         Forecast Methodology and Key Assumptions

17.3.         Global Autoinjectors Market, 2020-2030 (By Value)

17.3.1.      Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Value)

17.3.2.      Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.3.      Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.3.4.      Autoinjectors Market in North America, 2020-2030 (By Value)

17.3.4.1.    Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (By Value)

17.3.4.2.    Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.4.3.    Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.3.5.      Autoinjectors Market in Europe, 2020-2030 (By Value)

17.3.5.1.    Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (By Value)

17.3.5.2.    Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.5.3.    Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.3.6.      Autoinjectors Market in Asia Pacific, 2020-2030 (By Value)

17.3.6.1.    Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.3.6.2.    Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.6.3.    Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.3.7.      Autoinjectors Market in Rest of the World, 2020-2030 (By Value)

17.3.7.1.    Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.3.7.2.    Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.7.3.    Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.4.         Global Autoinjectors Market, 2020-2030 (By Volume)

17.4.1.      Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Volume)

17.4.2.      Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Volume)

17.4.3.      Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.4.4.      Autoinjectors Market in North America, 2020-2030 (By Volume)

17.3.4.1.    Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (By Volume)

17.3.4.2.    Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.3.4.3.    Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.3.5.      Autoinjectors Market in Europe, 2020-2030 (By Volume)

17.3.5.1.    Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.3.5.2.    Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.3.5.3.    Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.3.6.      Autoinjectors Market in Asia Pacific, 2020-2030 (By Volume)

17.3.6.1.    Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.3.6.2.    Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.3.6.3.    Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.3.7.      Autoinjectors Market in Rest of the World, 2020-2030 (By Volume)

17.3.7.1.    Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.3.7.2.    Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.3.7.3.    Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.5.         Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Value)

17.5.1.      Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (By Value)

17.5.1.1.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (By Value)

17.5.1.2.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.5.1.3.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.5.2.      Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (By Value)

17.5.2.1.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (By Value)

17.5.2.2.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.5.2.3.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.5.3.      Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (By Value)

17.5.3.1.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.5.3.2.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.5.3.3.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.5.4.      Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (By Value)

17.5.4.1.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.5.4.2.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.5.4.3.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.6.         Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Volume)

17.6.1.      Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (By Volume)

17.6.1.1.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (By Volume)

17.6.1.2.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.6.1.3.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.6.2.      Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (By Volume)

17.6.2.1.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.6.2.2.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.6.2.3.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.6.3.      Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (By Volume)

17.6.3.1.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.6.3.2.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.6.3.3.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.6.4.      Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (By Volume)

17.6.4.1.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.6.4.2.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.6.4.3.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.7.         Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Value)

17.7.1.      Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (By Value)

17.7.1.1.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (By Value)

17.7.1.2.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.7.1.3.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.7.2.      Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (By Value)

17.7.2.1.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (By Value)

17.7.2.2.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.7.2.3.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.7.3.      Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (By Value)

17.7.3.1.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.7.3.2.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.7.3.3.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.7.4.      Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (By Value)

17.7.4.1.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.7.4.2.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.7.4.3.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.8.         Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Volume)

17.8.1.      Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (By Volume)

17.8.1.1.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (By Volume)

17.8.1.2.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.8.1.3.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.8.2.      Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (By Volume)

17.8.2.1.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.8.2.2.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.8.2.3.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.8.3.      Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (By Volume)

17.8.3.1.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.8.3.2.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.8.3.3.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.8.4.      Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (By Volume)

17.8.4.1.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.8.4.2.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.8.4.3.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.9.         Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Value)

17.9.1.      Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (By Value)

17.9.1.1.    Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (By Value)

17.9.1.2.    Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.9.1.3.    Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.9.2.      Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (By Value)

17.9.2.1.    Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (By Value)

17.9.2.2.    Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.9.2.3.    Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.9.3.      Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (By Value)

17.9.3.1.    Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.9.3.2.    Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.9.3.3.    Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.9.4.      Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (By Value)

17.9.4.1.    Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.9.4.2.    Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.9.4.3.    Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.10.       Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Volume)

17.10.1.     Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (By Volume)

17.10.1.1.  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (By Volume)

17.10.1.2.  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.10.1.3.  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.10.2.     Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (By Volume)

17.10.2.1.  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.10.2.2.  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.10.2.3.  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.10.3.     Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (By Volume)

17.10.3.1.  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.10.3.2.  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.10.3.3.  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.10.4.     Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (By Volume)

17.10.4.1.  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.10.4.2.  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.10.4.3.  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.11.       Global Autoinjectors Market for Migraine, 2020-2030 (By Value)

17.11.1.     Autoinjectors Market for Migraine in North America, 2020-2030 (By Value)

17.11.1.1.  Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (By Value)

17.11.1.2.  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.11.1.3.  Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.11.2.     Autoinjectors Market for Migraine in Europe, 2020-2030 (By Value)

17.11.2.1.  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (By Value)

17.11.2.2.  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.11.2.3.  Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.11.3.     Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (By Value)

17.11.3.1.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.11.3.2.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.11.3.3.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.11.4.     Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (By Value)

17.11.4.1.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.11.4.2.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.11.4.3.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.12.       Global Autoinjectors Market for Migraine, 2020-2030 (By Volume)

17.12.1.     Autoinjectors Market for Migraine in North America, 2020-2030 (By Volume)

17.12.1.1.  Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (By Volume)

17.12.1.2.  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.12.1.3.  Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.12.2.     Autoinjectors Market for Migraine in Europe, 2020-2030 (By Volume)

17.12.2.1.  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.12.2.2.  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.12.2.3.  Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.12.3.     Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (By Volume)

17.12.3.1.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.12.3.2.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.12.3.3.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.12.4.     Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (By Volume)

17.12.4.1.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.12.4.2.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.12.4.3.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.13.       Global Autoinjectors Market for Diabetes, 2020-2030 (By Value)

17.13.1.     Autoinjectors Market for Diabetes in North America, 2020-2030 (By Value)

17.13.1.1.  Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (By Value)

17.13.1.2.  Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.13.1.3.  Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.13.2.     Autoinjectors Market for Diabetes in Europe, 2020-2030 (By Value)

17.13.2.1.  Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (By Value)

17.13.2.2.  Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.13.2.3.  Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.13.3.     Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (By Value)

17.13.3.1.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.13.3.2.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.13.3.3.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.13.4.     Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (By Value)

17.13.4.1.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.13.4.2.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.13.4.3.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.14.       Global Autoinjectors Market for Diabetes, 2020-2030 (By Volume)

17.14.1.     Autoinjectors Market for Diabetes in North America, 2020-2030 (By Volume)

17.14.1.1.  Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (By Volume)

17.14.1.2.  Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.14.1.3.  Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.14.2.     Autoinjectors Market for Diabetes in Europe, 2020-2030 (By Volume)

17.14.2.1.  Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.14.2.2.  Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.14.2.3.  Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.14.3.     Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (By Volume)

17.14.3.1.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.14.3.2.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.14.3.3.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.14.4.     Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (By Volume)

17.14.4.1.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.14.4.2.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.14.4.3.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.15.       Global Autoinjectors Market for Other Indications, 2020-2030 (By Value)

17.15.2.     Autoinjectors Market for Other Indications in North America, 2020-2030 (By Value)

17.15.2.1.  Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (By Value)

17.15.2.2.  Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.15.2.3.  Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.15.3.     Autoinjectors Market for Other Indications in Europe, 2020-2030 (By Value)

17.15.3.1.  Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (By Value)

17.15.3.2.  Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.15.3.3.  Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.15.4.     Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (By Value)

17.15.4.1.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.15.4.2.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.15.4.3.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.15.5.     Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (By Value)

17.15.5.1.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.15.5.2.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.15.5.3.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.16.       Global Autoinjectors Market for Other Indications, 2020-2030 (By Volume)

17.16.1.     Autoinjectors Market for Other Indications in North America, 2020-2030 (By Volume)

17.16.1.1.  Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (By Volume)

17.16.1.2.  Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.16.1.3.  Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.16.2.     Autoinjectors Market for Other Indications in Europe, 2020-2030 (By Volume)

17.16.2.1.  Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.16.2.2.  Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.16.2.3.  Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.16.3.     Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (By Volume)

17.16.3.1.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.16.3.2.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.16.3.3.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.16.4.     Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (By Volume)

17.16.4.1.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.16.4.2.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.16.4.3.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

18.            CONCLUSION

18.1.         Rising Incidence of Chronic Illnesses had Created a Growing Preference for Devices that Enable Self-Medication

18.2.         Given their Numerous Benefits, Autoinjector have Emerged as Potent Drug Delivery Tools

18.3.         Several Combination Products Have Already been Approved, while Many are Under Development

18.4.         Majority of the Available Products are Disposable; However, Reusable Devices are Gradually Gaining Popularity

18.5.         Ongoing Research Efforts Have Resulted in the Introduction of Robust Technology Platforms, Enabling the Incorporation of Novel and Advanced Features

18.6.         The Market is Expected to Evolve at a Steady Pace with Developed Nations Retaining the Majority Share, Over the Coming Decade

18.7.         Concluding Remarks

                

19.            INTERVIEW TRANSCRIPTS

19.1.         Chapter Overview

19.2.         DALI Medical Devices

19.2.1.      Company Snapshot

19.2.2.      Interview Transcript: David Daily, CEO and Co-Founder

 

19.3.         PHC

19.3.1.      Company Snapshot

19.3.2.      Interview Transcript: Douglas Marenzi, Managing Director

                

19.4.         Elcam Medical

19.4.1.      Company Snapshot

19.4.2.      Interview Transcript: Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices

 

19.5.         IDEO

19.5.1.      Company Snapshot

19.5.2.      Interview Transcript: Jesse Fourt, Design Director

 

19.6.         Bill & Melinda Gates Foundation

19.6.1.      Company Snapshot

19.6.2.      Interview Transcript: Dennis Lee, Senior Program Officer in CMC

                

20.            APPENDIX 1: TABULATED DATA

                

21.            APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

 

Ben Johnson

The global autoinjectors market is projected to grow at an annualized rate of over 10%, till 2030

4 min read

Autoinjectors have become an important part of modern healthcare, having demonstrated the potential to address a number of parenteral drug delivery related adverse events, and improve medication adherence among patients

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Autoinjectors Market (3rd Edition), 2020-2030.

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of developers engaged in the development and / or manufacturing autoinjectors. 

§  A detailed assessment of current landscape of companies that are developing drugs in combination with autoinjectors.

§  A competitiveness analysis of various disposable and reusable autoinjectors.

§  A detailed brand positioning analysis of leading industry players highlighting the current perceptions regarding their proprietary brands.

§  A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future.

§  A list of key opinion leaders (KOLs) within this domain with significant contributions in clinical trials and filing patent applications.

§  Detailed case studies on the most commonly targeted indications of the approved autoinjector products.

§  A case study on the role of CMOs offering services for drug delivery devices.

§  A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.

§  Elaborate profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  • Usability 

§  Disposable

§  Reusable

  • Route of Administration

§  Subcutaneous

§  Intramuscular

  • Type of Molecule

§  Monoclonal Antibody

§  Peptide

§  Protein

§  Small Molecule

  • Therapeutic Indication

§  Anaphylaxis

§  Asthma

§  Multiple Sclerosis

§  Rheumatoid Arthritis

§  Migraine

§  Diabetes

§  Other Indications

  • Key Geographies

§  North America

§  Europe

§  Asia-Pacific

§  Rest of the World

 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:

§  David Daily (CEO and Co-founder, DALI Medical Devices)

§  Dennis Lee (Senior Program Officer in CMC, Bill & Melinda Gates Foundation)

§  Douglas Marenzi (Managing Director, PHC Injection Technologies)

§  Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical)

§  Jesse Fourt (Design Director, IDEO)

 

Key companies covered in the report

§  Antares Pharma

§  Consort Medical (Previously Bespak)

§  DALI Medical Devices

§  Elcam Medical (E3D Elcam Drug Delivery Devices)

§  Jiangsu Delfu Medical Devices

§  Oval Medical Technologies

§  Owen Mumford

§  SHL Group

§  Union Medico®

§  Ypsomed

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html

 

Other Recent Offerings

1.      Prefilled Syringes Market (5th Edition), 2019-2030

2.      Novel Vaccine Delivery Devices Market, 2019-2030

3.      Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Ben Johnson

The “Gene Therapy Market (3rd Edition), 2019-2030” report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies and genome editing therapies.

7 min read

To order this detailed 670+ page report, please visit this link

 

Key Inclusions

§  A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, key therapeutic areas (cardiovascular disorders, muscular disorders, neurological disorders, ocular disorders, oncology and others) and target disease indication(s), information on gene type, type of vector used, type of therapy (ex vivo and in vivo), mechanism of action, type of gene modification (gene augmentation, oncolytic viral therapy and others) and special drug designation (if any).

§  A discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vectors.

§  A world map representation, depicting the most active geographies, in terms of the presence of companies engaged in developing gene therapies, and a bull's eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy (ex vivo and in vivo).

§  A discussion on the regulatory landscape related to gene therapies across various geographies, namely North America (the US and Canada), Europe and Asia-Pacific (Australia, China, Japan and South Korea), providing details related to the various challenges associated with obtaining reimbursements for gene therapies.

§  Detailed profiles of marketed and phase II/III and gene therapies, including a brief history of development, information on current development status, mechanism of action, affiliated technology, strength of patent portfolio, dosage and manufacturing details, along with information on the developer company.

§  An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development, namely prior to drug launch, at / during drug launch and post-marketing.

§  A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies, featuring detailed profiles of technologies that were / are being used for the development of four or more products / product candidates.

§  An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016. The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC classification, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.

§  An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019. The analysis also provides information on the key value drivers and deal multiples related to the mergers and acquisitions that we came across.

§  An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.

§  An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of gene therapies under development, funding information, partnership activity and strength of patent portfolio.

§  A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors. The study also includes a detailed discussion on the manufacturing processes associated with various types of vectors.

§  A discussion on the various operating models adopted by gene therapy developers for supply chain management, highlighting the stakeholders involved, factors affecting the supply of therapeutic products and challenges encountered by developers across the different stages of the gene therapy supply chain.

§  An analysis of the various factors that are likely to influence the pricing of gene-based therapies, featuring different models / approaches that may be adopted by manufacturers to decide the prices of these therapies.

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

§  Key therapeutic areas

§  Autoimmune disorders

§  Cardiovascular diseases

§  Genetic disorders

§  Hematological disorders

§  Metabolic disorders

§  Ophthalmic disorders

§  Oncological disorders

§  Others

 

§  Type of vector

§  Adeno associated virus

§  Adenovirus

§  Herpes simplex virus type 1

§  Lentivirus

§  Plasmid DNA

§  Retrovirus

§  Vaccinia Virus

 

§  Type of therapy

§  Ex vivo

§  In vivo

 

§  Type of gene modification

§  Gene augmentation

§  Immunotherapy

§  Oncolytic therapy

§  Others

 

§  Route of administration

§  Intraarticular

§  Intracerebellar

§  Intramuscular

§  Intradermal

§  Intravenous

§  Intravitreal

§  Intravesical

§  Subretinal

§  Others

 

§  Key geographical regions

§  North America

§  Europe

§  Asia-Pacific

 

The report includes detailed transcripts of discussions held with the following experts:

§  Adam Rogers (CEO, Hemera Biosciences)

§  Al Hawkins (CEO, Milo Biotechnology)

§  Buel Dan Rodgers (Founder & CEO, AAVogen)

§  Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)

§  Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)

§  Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)

§  Jeffrey Hung (CCO, Vigene Biosciences)

§  Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)

§  Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)

§  Robert Jan Lamers (CEO, Arthrogen)

§  Tom Wilton (Chief Business Officer, LogicBio Therapeutics)

 

To request sample pages, please visit this link            

 

Key Questions Answered

§  Who are the leading industry players in this market?

§  How big is the development pipeline and which new indications are coming in focus? Which vectors are being used for effective delivery of the therapeutic agents?

§  Who are the key investors in the gene therapy market?

§  How is the current and future market opportunity likely to be distributed across key market segments?

§  What kind of commercialization strategies are being adopted by gene therapy developers?

§  What are the different pricing models and reimbursement strategies used for gene therapies?

§  What are the prevalent R&D trends related to gene therapies?

§  What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?

§  Who are the key CMOs / CDMOs that claim to supply viral / plasmid vectors for gene therapy development?

 

You may also be interested in the following titles:

1.      Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)

2.      CAR-T Therapies Market (2nd Edition), 2019-2030

3.      Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Ben Johnson

Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated for the treatment of a variety of disease indications

3 min read

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

 

To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this link

 

The USD 11.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

§  Key therapeutic areas

§  Autoimmune disorders

§  Cardiovascular diseases

§  Genetic disorders

§  Hematological disorders

§  Metabolic disorders

§  Ophthalmic disorders

§  Oncological disorders

§  Others

 

§  Type of vector

§  Adeno associated virus

§  Adenovirus

§  Herpes simplex virus type 1

§  Lentivirus

§  Plasmid DNA

§  Retrovirus

§  Vaccinia Virus

 

§  Type of therapy

§  Ex vivo

§  In vivo

 

§  Type of gene modification

§  Gene augmentation

§  Immunotherapy

§  Oncolytic therapy

§  Others

 

§  Route of administration

§  Intraarticular

§  Intracerebellar

§  Intramuscular

§  Intradermal

§  Intravenous

§  Intravitreal

§  Intravesical

§  Subretinal

§  Others

 

§  Key geographical regions

§  North America

§  Europe

§  Asia-Pacific

 

The Gene Therapy Market (3rd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:

§  Advantagene

§  Advaxis

§  BioMarin

§  bluebird bio

§  FKD Therapies

§  Freeline Therapeutics

§  GenSight Biologics

§  Gradalis

§  Inovio Pharmaceuticals

§  Marsala Biotech

§  Orchard Therapeutics

§  Pfizer

§  Sarepta Therapeutics

§  Spark Therapeutics

§  Tocagen

§  Transgene

§  uniQure Biopharma

§  VBL Therapeutics

§  ViroMed

 

Table of Contents

 

1. Preface

 

2. Executive Summary

 

3. Introduction

 

4. Gene Delivery Vectors

 

5. Regulatory Landscape and Reimbursement Scenario

 

6. Competitive Landscape

 

7. Marketed Gene Therapies

 

8. Key Commercialization Strategies

 

9. Late Stage (Phase II/III and Above) Gene Therapies

 

10. Emerging Technologies

 

11. Promising Therapeutics Areas

 

12. Patent Analysis

 

13. Mergers and Acquisitions

 

14. Funding and Investment Analysis

 

15. Cost Price Analysis

 

16. Big Pharma Players: Analysis of Gene Therapy Related Initiatives

 

17. Market Forecast and Opportunity Analysis

 

18. Vector Manufacturing

 

19. Case Study: Gene Therapy Supply Chain

 

20. Conclusion

 

21. Interview Transcripts

 

22. Appendix 1: Tabulated Data

 

23. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Ben Johnson

The gene therapy market is projected to grow at an annualized rate of 45%, till 2030

19 min read

Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this link

 

Key Market Insights

§  In the past four years, more than 31,000 patents related to gene therapies and gene editing have been filed / granted; this is indicative of the heightened pace of research in this domain

§  Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated for the treatment of a variety of disease indications

§  Most of the therapeutic leads are in the early stages of clinical development; a variety of viral and non-viral vectors are being used to introduce different types of gene modifications in such therapies

§  Although start-ups and mid-sized companies are spearheading the innovation, several big biopharmaceutical companies are also actively engaged

§  With multiple approved products and several under development, price is one of the major concerns in this market; the future is likely to witness the establishment of more affordable pricing and reimbursement strategies

§  As several candidates progress towards approval, developers are exploring diverse commercialization strategies to be implemented across different stages of a product’s launch cycle

§  CMOs offering vector manufacturing services have become an integral part of the gene therapy supply chain, owing to their ability to overcome the various associated challenges

§  Several investors, having realized the untapped opportunity within this emerging segment of genetic disorders, have invested over USD 16.5 billion across 280 instances, in the period between 2014 and 2019

§  Overall, prevalent trends indicate that the market for gene therapies is poised to grow significantly as multiple late stage molecules get commercialized in the near future for the treatment of different therapeutic areas

§  The projected future opportunity is expected to be distributed across different types of gene modifications, therapy delivery routes and key geographical regions

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

 

Table of Contents

 

1.         PREFACE
1.1.      Scope of the Report
1.2.      Research Methodology
1.3.      Chapter Outlines

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.      Context and Background

3.2.      Evolution of Gene Therapies

3.3.      Classification of Gene Therapies

3.3.1.    Somatic and Germline Gene Therapy

3.3.2.    Ex Vivo and In Vivo Gene Therapy

3.4.      Routes of Administration

3.5.      Mechanism of Action of Gene Therapies

3.6.      Concept of Gene Editing

3.7.      Advantages and Disadvantages of Gene Therapies

3.8.      Ethical and Social Concerns Related to Gene Therapies

 

3.9.      Future Constraints and Challenges Related to Gene Therapies

3.9.1.    Concerns Related to Therapy Development

3.9.2.    Concerns Related to Manufacturing

3.9.3.    Concerns Related to Commercial Viability

 

4.         GENE DELIVERY VECTORS

4.1.      Chapter Overview

4.2.      Viral Vectors

4.2.1     Types of Viral Vectors

4.2.1.1. Adeno-associated Viral Vectors

4.2.1.1.1. Overview

4.2.1.1.2. Design

4.2.1.1.3. Advantages

4.2.1.1.4. Limitations

 

4.2.1.2. Adenoviral Vectors

4.2.1.2.1. Overview

4.2.1.2.2. Design

4.2.1.2.3. Advantages

4.2.1.2.4. Limitations

 

4.2.1.3. Lentiviral Vectors

4.2.1.3.1. Overview

4.2.1.3.2. Design

4.2.1.3.3. Advantages

4.2.1.3.4. Limitations

 

4.2.1.4. Retroviral Vectors

4.2.1.4.1. Overview

4.2.1.4.2. Design

4.2.1.4.3. Advantages

4.2.1.4.4. Limitations

 

4.2.1.5. Other Viral Vectors

4.2.1.5.1. Alphavirus

4.2.1.5.2. Herpes Simplex Virus

4.2.1.5.3. Simian Virus

4.2.1.5.4. Vaccinia Virus

 

4.3.      Non-Viral Vectors

4.3.1.    Types of Non-Viral Vectors

4.3.1.1. Plasmid DNA

4.3.1.2. Liposomes, Lipoplexes and Polyplexes

4.3.1.3. Oligonucleotides

 

4.4.      Methods of Transfection

4.4.1.    Biolistic Method

4.4.2.    Electroporation

4.4.3.    Receptor Mediated Gene Delivery

4.4.4.    Gene Activated Matrix (GAM)

 

5.         REGULATORY LANDSCAPE AND REIMBURSEMENT SCENARIO

5.1.      Chapter Overview

5.2.      Regulatory Guidelines in North America

5.2.1.    The US Scenario

5.2.2.    The Canadian Scenario

5.3.      Regulatory Guidelines in Europe

5.4.      Regulatory Guidelines in Asia Pacific

5.4.1.    Chinese Scenario

5.4.2.    Japanese Scenario

5.4.3.    South Korean Scenario

5.4.4.    Australian Scenario

5.5.      Reimbursement Scenario

5.5.1.    Challenges Related to Reimbursement

5.6.      Payment Models for Gene Therapies

 

6.         COMPETITIVE LANDSCAPE

6.1.      Chapter Overview

6.2.      Gene Therapy Market: Clinical and Commercial Pipeline

6.2.1.    Analysis by Phase of Development

6.2.2.    Analysis by Therapeutic Area

6.2.3.    Analysis by Type of Vector Used

6.2.4.    Analysis by Type of Gene

6.2.5.    Analysis by Type of Modification

6.2.6.    Analysis by Type of Gene Therapy

6.2.7.    Analysis by Route of Administration

 

6.3.      Gene Therapy Market: Early Stage Pipeline

6.3.1.    Analysis by Stage of Development

6.3.2.    Analysis by Therapeutic Area

6.3.3.    Analysis by Type of Vector Used

6.3.4.    Analysis by Type of Gene

6.3.5.    Analysis by Type of Modification

6.3.6.    Analysis by Type of Gene Therapy

 

6.4.      Gene Therapy: Special Designation Awarded

6.4.1.    Analysis by Special Designation Awarded

6.5.      Key Players: Analysis by Number of Product Candidates

6.6.      Developer Landscape

6.6.1.    Distribution by Year of Establishment

6.6.2.    Distribution by Size of Developer

6.6.3.    Distribution by Geographical Location

6.7.      Regional Landscape

 

7.         MARKETED GENE THERAPIES

7.1.      Chapter Overview

7.2.      Gendicine® (Shenzhen Sibiono GeneTech)

7.2.1.    Company Overview

7.2.2.    Development Timeline

7.2.3.    Mechanism of Action and Vectors Used

7.2.4.    Target Indication(s)

7.2.5.    Current Status of Development

7.2.6.    Manufacturing, Dosage and Sales

 

7.3.      Oncorine® (Shanghai Sunway Biotech)

7.3.1.    Company Overview

7.3.2.    Development Timeline

7.3.3.    Mechanism of Action and Vectors Used

7.3.4.    Target Indication(s)

7.3.5.    Current Status of Development

7.3.6.    Manufacturing, Dosage and Sales

 

7.4.      Rexin-G® (Epeius Biotechnologies)

7.4.1.    Company Overview

7.4.2.    Development Timeline

7.4.3.    Mechanism of Action and Vector Used

7.4.4.    Target Indication(s)

7.4.5.    Current Status of Development

7.4.6.    Manufacturing, Dosage and Sales

 

7.5.      Neovasculgen® (Human Stem Cells Institute)

7.5.1.    Company Overview

7.5.2.    Development Timeline

7.5.3.    Mechanism of Action and Vectors Used

7.5.4.    Target Indication(s)

7.5.5.    Current Status of Development

7.5.6.    Manufacturing, Dosage and Sales

 

7.6.      Imlygic® (Amgen)

7.6.1.    Company Overview

7.6.2.    Development Timeline

7.6.3.    Mechanism of Action and Vectors Used

7.6.4.    Target Indication(s)

7.6.5.    Current Status of Development

7.6.6.    Manufacturing, Dosage and Sales

 

7.7.      Strimvelis® (Orchard Therapeutics)

7.7.1.    Company Overview

7.7.2.    Development Timeline

7.7.3.    Mechanism of Action and Vectors Used

7.7.4.    Target Indication(s)

7.7.5.    Current Status of Development

7.7.6.    Manufacturing, Dosage and Sales

 

7.8.      Invossa™ (Kolon TissueGene)

7.8.1.    Company Overview

7.8.2.    Development Timeline

7.8.3.    Mechanism of Action and Vectors Used

7.8.4.    Target Indication(s)

7.8.5.    Current Status of Development

7.8.6.    Manufacturing, Dosage and Sales

 

7.9.      Luxturna™ (Spark Therapeutics)

7.9.1.    Company Overview

7.9.2.    Development Timeline

7.9.3.    Mechanism of Action and Vector Used

7.9.4.    Target Indication(s)

7.9.5.    Current Status of Development

7.9.6.    Manufacturing, Dosage and Sales

 

7.10.     Zolgensma™ (AveXis / Novartis)

7.10.1.  Company Overview

7.10.2.  Development Timeline

7.10.3.  Mechanism of Action and Vector Used

7.10.4.  Target Indication(s)

7.10.5.  Current Status of Development

7.10.6.  Manufacturing, Dosage and Sales

 

7.11.     Collategene® / Beperminogene Perplasmid (AnGes)

7.11.1.  Company Overview

7.11.2.  Development Timeline

7.11.3.  Mechanism of Action and Vector Used

7.11.4.  Target Indication(s)

7.11.5.  Current Status of Development

7.11.6.  Manufacturing, Dosage and Sales

 

7.12.     Zyntelgo™ (bluebird bio)

7.12.1.  Company Overview

7.12.2.  Development Timeline

7.12.3.  Mechanism of Action and Vector Used

7.12.4.  Target Indication(s)

7.12.5.  Current Status of Development

7.12.6.  Manufacturing, Dosage and Sales

 

8.         KEY COMMERCIALIZATION STRATEGIES

8.1.      Chapter Overview

8.2.      Successful Drug Launch Strategy: ROOTS Framework

8.3.      Successful Drug Launch Strategy: Product Differentiation

8.4.      Commonly Adopted Commercialization Strategies based on Development Stage of the Product

8.5.      Approved Gene Therapies

8.6.      Key Commercialization Strategies Adopted by Companies Focused on Gene Therapy

8.6.1.    Strategies Adopted Before Therapy Approval

8.6.2.    Strategies Adopted During / Post Therapy Approval

8.7.      Concluding Remarks

 

9.         LATE STAGE (PHASE II/III AND ABOVE) GENE THERAPIES

9.1.      Chapter Overview

9.2.      AMT-061: Overview of Therapy, Current Development Status and Clinical Results

9.3.      BIIB111 (NSR-REP1): Overview of Therapy, Current Development Status and Clinical Results

9.4.      BIIB112 (NSR-RPGR): Overview of Therapy, Current Development Status and Clinical Results

9.5.      BMN 270 (valoctocogene roxaparvovec): Overview of Therapy, Current Development Status and Clinical Results

9.6.      E10A: Overview of Therapy, Current Development Status and Clinical Results

9.7.      FLT180a: Overview of Therapy, Current Development Status and Clinical Results

9.8.      GS010: Overview of Therapy, Current Development Status and Clinical Results

9.9.      Instiladrin®: Overview of Therapy, Current Development Status and Clinical Results

9.10.     Lenti-D™: Overview of Therapy, Current Development Status and Clinical Results

9.11.     LYS-SAF302: Overview of Therapy, Current Development Status and Clinical Results

9.12.     OTL-101: Overview of Therapy, Current Development Status and Clinical Results

9.13.     OTL-103: Overview of Therapy, Current Development Status and Clinical Results

9.14.     OTL-200: Overview of Therapy, Current Development Status and Clinical Results

9.15.     Pexa-Vec (pexastimogene devacirepvec): Overview of Therapy, Current Development Status and Clinical Results

9.16.     PF-06838435 (fidanacogene elaparvovec): Overview of Therapy, Current Development Status and Clinical Results

9.17.     ProstAtak®: Overview of Therapy, Current Development Status and Clinical Results

9.18.     SPK-8011: Overview of Therapy, Current Development Status and Clinical Results

9.19.     Toca 511 (vocimagene amiretrorepvec): Overview of Therapy, Current Development Status and Clinical Results

9.20.     VB-111 (ofranergene obadenovec): Overview of Therapy, Current Development Status and Clinical Results

9.21.     VGX-3100: Overview of Therapy, Current Development Status and Clinical Results

9.22.     Vigil®: Overview of Therapy, Current Development Status and Clinical Results

9.23.     VM202 (donaperminogene seltoplasmid): Overview of Therapy, Current Development Status and Clinical Results

 

10.       EMERGING TECHNOLOGIES

10.1.     Chapter Overview

10.2.     Gene Editing Technologies

10.2.1.  Overview

10.2.2.  Applications

 

10.3.     Emerging Gene Editing Platforms

10.3.1.  CRISPR / Cas9 System

10.3.2.  TALENs

10.3.3.  megaTAL

10.3.4.  Zinc Finger Nuclease

 

10.4.     Gene Expression Regulation Technologies

10.5.     Technology Platforms for Developing / Delivering Gene Therapies

 

11.       PROMISING THERAPEUTICS AREAS

11.1.     Chapter Overview

11.2      Analysis by Special Designations Awarded

 

11.3.     Autoimmune Disorders

11.3.1.  Analysis by Target Indication

11.3.2.  Analysis by Type of Vector Used

 

11.4.     Cardiovascular Diseases

11.4.1.  Analysis by Target Indication

11.4.2.  Analysis by Type of Vector Used

11.5.     Dermatological Disorders

11.5.1.  Analysis by Target Indication

11.5.2.  Analysis by Type of Vector Used

 

11.6.     Genetic Disorders

11.6.1.  Analysis by Target Indication

11.6.2.  Analysis by Type of Vector Used

 

11.7.     Hematological Disorders

11.7.1.  Analysis by Target Indication

11.7.2.  Analysis by Type of Vector Used

 

11.8.     Infectious Diseases

11.8.1.  Analysis by Target Indication

11.8.2.  Analysis by Type of Vector Used

 

11.9.     Metabolic Disorders

11.9.1.  Analysis by Target Indication

11.9.2.  Analysis by Type of Vector Used

 

11.10.   Muscle-related Diseases

11.10.1. Analysis by Target Indication

11.10.2. Analysis by Type of Vector Used

 

11.11.   Nervous System Disorders

11.11.1. Analysis by Target Indication

11.11.2. Analysis by Type of Vector Used

 

11.12.   Oncological Disorders

11.12.1. Analysis by Target Indication

11.12.2. Analysis by Type of Vector Used

 

11.13.   Ophthalmic Diseases

11.13.1. Analysis by Target Indication

11.13.2. Analysis by Type of Vector Used

 

12.       PATENT ANALYSIS

12.1.     Chapter Overview

12.2.     Gene Therapy-related Patents

12.2.1.  Scope and Methodology

12.2.1.1. Analysis by Publication Year

12.2.1.2. Analysis by Geographical Location

12.2.1.3. Analysis by CPC Classification

12.2.1.4. Emerging Focus Areas

12.2.1.5. Leading Players: Analysis by Number of Patents

12.2.1.6. Patent Benchmark Analysis

12.2.1.7. Patent Valuation Analysis

 

12.3.     Gene Editing-related Patents

12.3.1.  Scope and Methodology

12.3.1.1. Analysis by Publication Year

12.3.1.2. Analysis by Geographical Location

 

12.3.1.3. Analysis by CPC Classification

12.3.1.4. Emerging Focus Areas

12.3.1.5. Leading Players: Analysis by Number of Patents

12.3.1.6. Patent Benchmark Analysis

12.3.1.7. Patent Valuation Analysis

 

12.4.     Overall Intellectual Property Portfolio: Analysis by Type of Organization

 

13.       MERGERS AND ACQUISITIONS

13.1.     Chapter Overview

13.2.     Merger and Acquisition Models

13.3.     Gene Therapy: Mergers and Acquisitions

13.3.1.  Analysis by Year of Mergers and Acquisitions

13.3.2.  Analysis by Type of Mergers and Acquisitions

13.3.3.  Regional Analysis

13.3.3.1. Continent-wise Distribution

13.3.3.2. Intercontinental and Intracontinental Deals

13.3.3.3. Country-wise Distribution

13.3.4.  Analysis by Key Value Drivers

13.3.4.1. Analysis by Key Value Drivers and Year of Acquisition

13.3.5.  Analysis by Phase of Development of the Acquired Company’s Product

13.3.6.  Analysis by Therapeutic Area

 

14.       FUNDING AND INVESTMENT ANALYSIS

14.1.     Chapter Overview

14.2.     Types of Funding

14.3.     Funding and Investment Analysis

14.3.1.  Analysis by Number of Funding Instances

14.3.2.  Analysis by Amount Invested

14.3.3.  Analysis by Type of Funding

14.3.4.  Analysis by Amount Invested across Different Types of Therapies

14.3.5.  Regional Analysis by Amount Invested

14.3.6.  Most Active Players

14.3.7.  Key Investors

14.3.8.  Analysis by Stage of Development

14.4.     Concluding Remarks

 

15.       COST PRICE ANALYSIS

15.1.     Chapter Overview

15.2.     Gene Therapy Market: Factors Contributing to the Price of Gene Therapies

15.3.     Gene Therapy Market: Pricing Models

15.3.1.  On the Basis of Associated Product / Component Costs

15.3.2.  On the Basis of Competition

15.3.3.  On the Basis of Patient Segment

15.3.4.  On the Basis of Opinions of Industry Experts

 

16.       BIG PHARMA PLAYERS: ANALYSIS OF GENE THERAPY RELATED INITIATIVES

16.1.     Chapter Overview

16.2.     Top Pharmaceutical Companies

16.2.1.  Analysis by Therapeutic Area

16.2.2.  Analysis by Type of Vector Used

16.2.3.  Analysis by Type of Modification

16.2.4.  Analysis by Type of Gene Therapy

16.3.     Other Big Pharma Players

 

17.       MARKET FORECAST AND OPPORTUNITY ANALYSIS

17.1.     Chapter Overview

17.2.     Scope and Limitations

17.3.     Key Assumptions and Forecast Methodology

17.4.     Overall Gene Therapy Market, 2019-2030

17.4.1.  Gene Therapy Market: Analysis by Type of Gene Modification

17.4.2.  Gene Therapy Market: Analysis by Type of Therapy

17.4.3.  Gene Therapy Market: Analysis by Type of Vector Used

17.4.4.  Gene Therapy Market: Analysis by Therapeutic Area

17.4.5.  Gene Therapy Market: Analysis by Route of Administration

17.4.6.  Gene Therapy Market: Analysis by Geography

 

17.5.     Gene Therapy Market: Value Creation Analysis

 

17.6.     Gene Therapy Market: Product-wise Sales Forecasts

17.6.1.  Gendicine®

17.6.1.1. Target Patient Population

17.6.1.2. Sales Forecast

17.6.1.3. Net Present Value

17.6.1.4. Value Creation Analysis

 

17.6.2.  Oncorine®

17.6.2.1. Target Patient Population

17.6.2.2. Sales Forecast

17.6.2.3. Net Present Value

17.6.2.4. Value Creation Analysis

 

17.6.3.  Rexin-G®

17.6.3.1. Target Patient Population

17.6.3.2. Sales Forecast

17.6.3.3. Net Present Value

17.6.3.4. Value Creation Analysis

 

17.6.4.  Neovasculgen®

17.6.4.1. Target Patient Population

17.6.4.2. Sales Forecast

17.6.4.3. Net Present Value

17.6.4.4. Value Creation Analysis

 

17.6.5.  Strimvelis®

17.6.5.1. Target Patient Population

17.6.5.2. Sales Forecast

17.6.5.3. Net Present Value

17.6.5.4. Value Creation Analysis

 

17.6.6.  Imlygic®

17.6.6.1. Target Patient Population

17.6.6.2. Sales Forecast

17.6.6.3. Net Present Value

17.6.6.4. Value Creation Analysis

 

17.6.7.  Invossa™

17.6.7.1. Target Patient Population

17.6.7.2. Sales Forecast

17.6.7.3. Net Present Value

17.6.7.4. Value Creation Analysis

 

17.6.8.  Luxturna™

17.6.8.1. Target Patient Population

17.6.8.2. Sales Forecast

17.6.8.3. Net Present Value

17.6.8.4. Value Creation Analysis

 

17.6.9.  Zolgensma™

17.6.9.1. Target Patient Population

17.6.9.2. Sales Forecast

17.6.9.3. Net Present Value

17.6.9.4. Value Creation Analysis

 

17.6.10. Collategene® / Beperminogene Perplasmid

17.6.10.1. Target Patient Population

14.6.10.2. Sales Forecast

17.6.10.3. Net Present Value

17.6.10.4. Value Creation Analysis

 

17.6.11. Zyntelgo™

17.6.11.1. Target Patient Population

17.6.11.2. Sales Forecast

17.6.11.3. Net Present Value

17.6.11.4. Value Creation Analysis

 

17.6.12. AMT-061

17.6.12.1. Target Patient Population

17.6.12.2. Sales Forecast

17.6.12.3. Net Present Value

17.6.12.4. Value Creation Analysis

 

17.6.13. BIIB111

17.6.13.1. Target Patient Population

17.6.13.2. Sales Forecast

17.6.13.3. Net Present Value

17.6.13.4. Value Creation Analysis

 

17.6.14. BIIB112

17.6.14.1. Target Patient Population

17.6.14.2. Sales Forecast

17.6.14.3. Net Present Value

17.6.14.4. Value Creation Analysis

 

17.6.15. BMN 270

17.6.15.1. Target Patient Population

17.6.15.2. Sales Forecast

17.6.15.3. Net Present Value

17.6.15.4. Value Creation Analysis

 

17.6.16. E10A

17.6.16.1. Target Patient Population

17.6.16.2. Sales Forecast

17.6.16.3. Net Present Value

17.6.16.4. Value Creation Analysis

 

17.6.17. FLT180a

17.6.17.1. Target Patient Population

17.6.17.2. Sales Forecast

17.6.17.3. Net Present Value

17.6.17.4. Value Creation Analysis

 

17.6.18. GS010

17.6.18.1. Target Patient Population

17.6.18.2. Sales Forecast

17.6.18.3. Net Present Value

17.6.18.4. Value Creation Analysis

 

17.6.19. Instiladrin®

17.6.19.1. Target Patient Population

17.6.19.2. Sales Forecast

17.6.19.3. Net Present Value

17.6.19.4. Value Creation Analysis

 

17.6.20. Lenti-D™

17.6.20.1. Target Patient Population

17.6.20.2. Sales Forecast

17.6.20.3. Net Present Value

17.6.20.4. Value Creation Analysis

 

17.6.21. LYS-SAF302

17.6.21.1. Target Patient Population

17.6.21.2. Sales Forecast

17.6.21.3. Net Present Value

17.6.21.4. Value Creation Analysis

 

17.6.22. OTL-101

17.6.22.1. Target Patient Population

17.6.22.2. Sales Forecast

17.6.22.3. Net Present Value

17.6.22.4. Value Creation Analysis

 

17.6.23. OTL-103

17.6.23.1. Target Patient Population

17.6.23.2. Sales Forecast

17.6.23.3. Net Present Value

17.6.23.4. Value Creation Analysis

 

17.6.24. OTL-200

17.6.24.1. Target Patient Population

17.6.24.2. Sales Forecast

17.6.24.3. Net Present Value

17.6.24.4. Value Creation Analysis

 

17.6.25. Pexa-Vec

17.6.25.1. Target Patient Population

17.6.25.2. Sales Forecast

17.6.25.3. Net Present Value

17.6.25.4. Value Creation Analysis

 

17.6.26. PF-06838435

17.6.26.1. Target Patient Population

17.6.26.2. Sales Forecast

17.6. 26.3. Net Present Value

17.6.26.4. Value Creation Analysis

 

17.6.27. ProstAtak®

17.6.27.1. Target Patient Population

17.6.27.2. Sales Forecast

17.6.27.3. Net Present Value

17.6.27.4. Value Creation Analysis

 

17.6.28. SPK-8011

17.6.28.1. Target Patient Population

17.6.28.2. Sales Forecast

17.6.28.3. Net Present Value

17.6.28.4. Value Creation Analysis

 

17.6.29. Toca 511

17.6.29.1. Target Patient Population

17.6.29.2. Sales Forecast

17.6.29.3. Net Present Value

17.6.29.4. Value Creation Analysis

 

17.6.30. VB-111

17.6.30.1. Target Patient Population

17.6.30.2. Sales Forecast

17.6.30.3. Net Present Value

17.6.30.4. Value Creation Analysis

 

17.6.31. VGX-3100

17.6.31.1. Target Patient Population

17.6.31.2. Sales Forecast

17.6.31.3. Net Present Value

17.6.31.4. Value Creation Analysis

 

17.6.32. Vigil®

17.6.32.1. Target Patient Population

17.6.32.2. Sales Forecast

17.6.32.3. Net Present Value

17.6.32.4. Value Creation Analysis

 

17.6.33. VM202

17.6.33.1. Target Patient Population

17.6.33.2. Sales Forecast

17.6.33.3. Net Present Value

17.6.33.4. Value Creation Analysis

 

18.       VECTOR MANUFACTURING

18.1.     Chapter Overview

18.2.     Overview of Viral Vector Manufacturing

18.3.     Viral Vector Manufacturing Processes

18.3.1.  Mode of Vector Production

18.3.2.  Adherent and Suspension Cultures

18.3.3.  Unit Processes and Multiple Parallel Processes

18.3.4.  Cell Culture Systems for Production of Viral Vectors

18.3.5.  Culture Media Specifications

 

18.4.     Bioprocessing of Viral Vectors

18.4.1.  AAV Vector Production

18.4.2.  Adenoviral Vector Production

18.4.3.  Lentiviral Vector Production

18.4.4.  γ -Retroviral Vector Production

 

18.5.     Challenges Associated with Vector Manufacturing

18.6.     Companies Offering Contract Services for Viral and Plasmid Vectors

 

19.       CASE STUDY: GENE THERAPY SUPPLY CHAIN

19.1.     Chapter Overview

19.2.     Overview of the Gene Therapy Supply Chain

19.3.     Implementation of Supply Chain Models

19.4.     Logistics in Gene Therapy

19.4.1.  Logistics Processes for Autologous and Allogeneic Therapies

19.5.     Regulatory Supply Chain across the Globe

19.6.     Challenges Associated with Gene Therapy Supply Chain

19.7.     Optimizing Cell and Advanced Therapies Supply Chain Management

19.8.     Recent Developments and Upcoming Trends

 

20.       CONCLUSION

20.1.     Chapter Overview

20.2.     Key Takeaways

 

21.       INTERVIEW TRANSCRIPTS

21.1.     Chapter Overview

21.2.     Adam Rogers, Chief Executive Officer, Hemera Biosciences

21.3.     Al Hawkins, Chief Executive Officer, Milo Biotechnology

21.4.     Buel Dan Rodgers, Founder & Chief Executive Officer, AAVogen

21.5.     Cedric Szpirer, Executive & Scientific Director, Delphi Genetics

21.6.     Christopher Reinhard, Chief Executive Officer and Chairman, Gene Therapeutics (previously known as Cardium Therapeutics)

21.7.     Ryo Kubota, Chairman, President and Chief Executive Officer, Acucela

21.8.     Jeffrey HunG, Chief Commercial Officer, Vigene Biosciences

21.9.     Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager, PlasmidFactory

21.10.   Michael Tripletti, Chief Executive Officer, Myonexus Therapeutics

21.11.   Robert Jan Lamers, Chief Executive Officer, Arthrogen

21.12.   Tom Wilton, Chief Business Officer, LogicBio Therapeutics

 

22.       APPENDIX 1: TABULATED DATA

 

23.       APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]